Inogen Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Mortality and Increased Cost-Effectiveness Ratio
With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date.
- With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date.
- Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen.
- “The study highlights what we have known anecdotally about portable oxygen therapies, and Inogen devices,” said Kevin Smith, President and Chief Executive Officer.
- “We have long believed that mobile oxygen therapies, primarily portable oxygen concentrators, are associated with improved health outcomes, affordability, and patient quality of life.